Ditchcarbon
  • Contact
  1. Organizations
  2. GeneScience Pharmaceuticals Co., Ltd.
Public Profile
Pharmaceutical Preparation Manufacturing
CN
updated a month ago

GeneScience Pharmaceuticals Co., Ltd. Sustainability Profile

Company website

GeneScience Pharmaceuticals Co., Ltd., commonly referred to as GeneScience, is a leading biopharmaceutical company headquartered in China (CN). Established in 2002, the company has made significant strides in the biotechnology sector, focusing on the research, development, and production of innovative biopharmaceuticals. With a strong presence in both domestic and international markets, GeneScience excels in areas such as recombinant proteins, monoclonal antibodies, and biosimilars. Their flagship products, including the well-regarded EPO and G-CSF, are distinguished by their high quality and efficacy, setting them apart in a competitive landscape. Recognised for its commitment to advancing healthcare, GeneScience has achieved notable milestones, including numerous regulatory approvals and partnerships that enhance its market position. As a pioneer in the biopharmaceutical industry, GeneScience continues to drive innovation and improve patient outcomes globally.

DitchCarbon Score

How does GeneScience Pharmaceuticals Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

22

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

31

Industry Benchmark

GeneScience Pharmaceuticals Co., Ltd.'s score of 22 is lower than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.

21%

Let us know if this data was useful to you

GeneScience Pharmaceuticals Co., Ltd.'s reported carbon emissions

GeneScience Pharmaceuticals Co., Ltd., headquartered in China (CN), currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Changchun High-Tech Industry (Group) Co., Ltd., which may influence its climate commitments and reporting practices. As of now, GeneScience Pharmaceuticals has not established any documented reduction targets or commitments under the Science Based Targets initiative (SBTi) or other climate initiatives. This lack of specific targets suggests that the company may still be in the early stages of developing a comprehensive climate strategy. Given the absence of direct emissions data and reduction initiatives, it is essential for GeneScience Pharmaceuticals to consider setting measurable climate goals and participating in recognised frameworks to enhance its sustainability profile and align with industry standards.

How Carbon Intensive is GeneScience Pharmaceuticals Co., Ltd.'s Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. GeneScience Pharmaceuticals Co., Ltd.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is GeneScience Pharmaceuticals Co., Ltd.'s Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for GeneScience Pharmaceuticals Co., Ltd. is in CN, which we do not have grid emissions data for.

GeneScience Pharmaceuticals Co., Ltd.'s Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

GeneScience Pharmaceuticals Co., Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare GeneScience Pharmaceuticals Co., Ltd.'s Emissions with Industry Peers

HanchorBio Inc.

TW
•
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

TG Therapeutics, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 2 months ago

Jiangsu Chia Tai-Tianqing Pharmaceutical Co. Ltd

CN
•
Pharmaceutical Preparation Manufacturing
Updated 2 months ago

Conjupro Biotherapeutics Inc.

US
Updated 22 days ago

Beijing Mabworks Biotech Co., Ltd.

CN
Updated 11 days ago

Byondis B.V.

NL
•
Research and development services (73)
Updated about 2 months ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251030.3
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy